

101 10 2005  
PATENT & TRADEMARK OFFICE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of

Donald L. Durden

Application No. 10/770,725

Filed: February 3, 2004

For: "COMPOSITIONS AND METHODS:  
FOR IDENTIFYING AGENTS :  
WHICH MODULATE PTEN :  
FUNCTION AND PI-3 KINASE :  
PATHWAYS" :

Examiner: Misook Yu

Group Art Unit: 1642

Docket: 1857-IURTC.0024US-CON2

Certificate of Mailing Under 37 CFR §1.8(a)

I hereby certify that this Correspondence is being deposited on  
January 13, 2005 with the United States Postal Service as first-class mail  
in an envelope properly addressed to COMMISSIONER FOR PATENTS, P.O. Box  
1450, Alexandria, VA 22313-1450.

*Janice M. Nightlinger*  
Janice M. Nightlinger

SUPPLEMENTAL REQUEST FOR LISTING OF REFERENCES

Further to the Request for Listing of References filed on August 19, 2004 in the above-identified application, Applicant is submitting herewith two (2) Forms PTO-892 attached to Official Actions dated January 15, 2003 and September 17, 2003, respectively, listing references that were considered and made of record in connection with Applicants' parent U.S. Application No. 09/870,379, filed May 30, 2001.

It is respectfully requested that the references included in the Forms PTO-892 submitted herewith be also listed on the face of the patent granted on the above-identified application, in accordance with the following provisions of §609 of the Manual of Patent Examining Procedure:

[T]he examiner will consider information which has been considered by the Office in a parent application when examining (A) a continuation application filed under 37 CFR 1.53(b) or filed under former 37 CFR 160, (B) a divisional application filed under 37 CFR 1.53(b) or filed under form 37 CFR 1.60, or (C) a continuation-in-part application filed under 37 CFR 1.53(b). Such information need not be resubmitted in

the continuing application unless applicant desires  
the information to be printed on the patent.

In the event any fee is due in connection with the  
consideration of this request, the Commissioner is authorized  
to charge any such fee to the account of the undersigned  
attorneys, Deposit Account No. 04-1406.

Respectfully submitted,

DANN DORFMAN HERRELL and  
SKILLMAN, P.C.  
Attorneys for Applicant

By   
Kathleen D. Rigaut, Ph.D., J.D.  
Registration No. 43,047

KDR:jmn  
Enclosure

Telephone: 215-563-4100  
Facsimile: 215-563-4044  
Customer No. 000110

RECEIVED  
JUN 19 2003  
PATENT & TRADEMARK OFFICE  
INFORMATION  
DISCLOSURE  
STATEMENT  
JUN 19 2003  
SHEET 1 OF 1

Complete if known

Application Number: 09/870379	RECEIVE
Filing Date: May 30, 2001	JUN 20 2003
First Named Inventor: Donald L. Durden	TECH CENTER 1600/
Group Art Unit: 1642	
Examiner Name: Yu, Misook	
Attorney Docket Number: 1857-P02575US1	

### UNITED STATES PATENT DOCUMENTS

EXAMINER'S INITIALS	CITE NO.	PATENT NUMBER	ISSUE DATE MM-DD-YYYY	FIRST NAMED INVENTOR
MY	A1	6020199	02-01-2000	Monia, et al.

### FOREIGN PATENT DOCUMENTS

EXAMINER'S INITIALS	CITE NO.	DOCUMENT NUMBER	COUNTRY OR REGION	DATE OF PUBLICATION MM-DD-YYYY	FIRST NAMED INVENTOR OR APPLICANT

### OTHER PRIOR ART - NON-PATENT DOCUMENTS

EXAMINER'S INITIALS	CITE NO.	Include name of the author (in Capital Letters), title of the article (when appropriate), title of the item(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published
MY	C1	LI, DA-MING, et al., "PTEN/MMAC1/TEP1 suppresses the tumorigenicity and induces G <sub>1</sub> cell cycle arrest in human glioblastoma cells"; Proc. Natl. Acad. Sci. USA, 95:15406-15411 (1998)
	C2	LI, LIWU, et al., "A Family of Putative Tumor Suppressors Is Structurally and Functionally Conserved in Humans and Yeast"; J. Biological Chemistry, 272: 29403-29406 (1997)
	C3	LI, JING, et al., "PTEN, a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer"; Science 275: 1943-1947 (1997)
	C4	HUANG, HE, et al., "PTEN affects cell size, cell proliferation and apoptosis during Drosophila eye development"; Development 126: 5365-5372 (1999)
	C5	LEE, JIE-OH, et al., "Crystal Structure of the PTEN Tumor Suppressor: Implications for Its Phosphoinositide Phosphatase Activity and Membrane Association"; Cell, 99: 323-334 (1999)
	C6	SUN, HONG, et al., "PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3,4,5-trisphosphate and Akt/protein kinase B signaling pathway"; Proc. Natl. Acad. Sci. USA 96: 6199-6204 (1999)
✓	C7	GIRI, D., et al., "Inactivation of the PTEN tumor suppressor gene is associated with increased angiogenesis in clinically localized prostate carcinoma"; PubMed, Hum. Pathol. 30:419-24 [abstract] (1999)

EXAMINER'S SIGNATURE	Misook Y	DATE CONSIDERED	9-13-03
----------------------	----------	--------------------	---------